Actuate is a clinical-stage biopharmaceutical company dedicated to developing [cutting-edge] therapies for cancers with high unmet needs. The company’s product candidate, elraglusib is a small molecule GSK-3 inhibitor designed to restore balance in the NF-κB pathway, effectively reducing inflammation, chemoresistance, and tumor progression. Elraglusib injection is being developed as a potential monotherapy and as part of combination therapy in pancreatic cancer and Ewing sarcoma, while elraglusib oral tablet is being developed in solid cancers. The U.S. Food and Drug Administration (FDA) has granted elraglusib Fast Track and Orphan Drug designations for the treatment of pancreatic cancer.